NCT00216164 - Rituximab and Gemcitabine for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions

Lymphoma, B-Cell

Interventions

DRUG

Rituximab

Rituximab 375 mg/m2, day 1 of 21 day cycle

DRUG

Gemcitabine

Gemcitabine 1000 mg/m2, days 1 and 8 of 21 day cycle

Trial Locations (9)

Indiana University Cancer Center, Indianapolis

Quality Cancer Center (MCGOP), Indianapolis

Elkhart Clinic, Elkhart

Northern Indiana Cancer Research Consortium, South Bend

Fort Wayne Oncology & Hematology, Inc, Fort Wayne

Center for Cancer Care, Inc., P.C., New Albany

Oncology Hematology Associates of SW Indiana, Evansville

Providence Medical Group, Terre Haute

AP&S Clinic, Terre Haute